|Bid||39.90 x 800|
|Ask||43.40 x 900|
|Day's Range||42.46 - 43.40|
|52 Week Range||37.12 - 70.82|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.22|
In this article we are going to estimate the intrinsic value of PTC Therapeutics, Inc. ( NASDAQ:PTCT ) by taking the...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy (SMA) treated with Evrysdi were able to reach motor milestones such as sitting without support, rolling, crawling, standing unaided and walking independently.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company's Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a $6 billion division of the U.S. Department of Health and Human Services (HHS) and system of hospitals providing healthcare to more than two million Native Americans in the United States. Ms. Smith currently serves as Vice Chair at the VENG Group, a non-partisan g